XOMA Corporation Message Board
-
HCD122
The way I understand it Xoma and Novartis will be releasing Phase I data for HCD122 during a oncology get together Dec 5th. This is probably the next news we can look forward to.
Just came across this clinical trial starting for HCD122. Looks like they are beginning another Phase I, this time for Leukemia.
http://clinicaltrials.gov/ct/show/NCT00108108;jsessionid=4CBD94D008E9FAE73EECEF4A59906917?order=25-
Just a bit of history. Xoma had partnered up with Chir for HCD122. But then Chir was bought by Novartis and we didn't know if Novartis would go on with the HCD participation. With the data release in early Dec and now the beginning of this new Phase I it looks like Novartis is going to continue to move forward....which is good for Xoma.
- 2 Replies to larrys_s2
-
Yes, I am 100% agree with you
-
Dec/05/2007?
-
Novartis and Xoma are feeling good about HCD122 with the 3rd indication starting(leukemia). They are escalating the doses and the patient populations. Interesting that Novartis lists HCD122 as planned marketing for 2011 on their website.
- 2 Replies to gates_wanabe
-
I was wrong about 3rd indication, still the already known 2. I got a little carried away.
-
HCD122 is a fully human anti-CD40 antagonist antibody intended as a treatment for B-cell mediated diseases, including malignancies and autoimmune diseases. This antibody has a dual mechanism of action blocking a tumor cell growth and survival signal, as well as recruiting immune effector cells to kill tumor cells.
HCD122 is the product candidate selected under the multi-product antibody development and commercialization agreement for the treatment of cancer announced by Novartis and the Company.
In addition, there are a number of undisclosed preclinical stage programs that the Company is investigating with Novartis.
-
Dec-5-2007?
- 1 Reply to down00up04
-
I have been busy and haven't heard the replay of the CC about reorganization. I have read what a couple posted but no one mentioned HCD122. Since it is going public Dec 5th did Xoma say what they were going to do with HCD122??
-
In two weeks
- 1 Reply to down00up04
-
I dont think anything new is really going to be coming out. Most of the links everyone has provided show that phase I is goin well...what more can they possibly say that would be meaningful? I dont think this is the news they were talking about at the CC.
-
NVS expands clinical studies of HCD122 from cancer into others additional diseases, see you Dec-5-2007
-
-
Don't forget HCD122, it will be presented at Dec-5-2007 conference. We may get some great news at Nov-27-2007 presentation (http://biz.yahoo.com/pz/071115/131493.html).
Nasdaq 52 week range 2,331.57 - 2,861.51, now we are at 2,545. Already down over 315 points = 12%!!! -
More and more money will move into XOMA at recession time, because investors are look for growing stocks.
-
-
Novartis, is one of the buyers? may get more news next week?
- View More Messages
-